Status:

RECRUITING

MRI-guided Focused Ultrasound : Feasibility Study for the Treatment of Bone Metastases and osteoïd Osteoma

Lead Sponsor:

University Hospital, Strasbourg, France

Conditions:

Painful Bone Metastases

Superficial Osteoid Osteoma

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Ufoguide is a prospective single arm open study to assess the feasibility of a new type of HIFU system to treat bone tumors. HIFU is classically delivered by a transducer integrated in the MRI table....

Detailed Description

Ufoguide is a prospective single arm open study to assess the feasibility of a new type of HIFU system for the treatment of painful metastases (palliative intent) and osteoid osteoma (curative intent)...

Eligibility Criteria

Inclusion

  • Subject with one or more painful bone metastases (EVA≥5)
  • Subject with sub-perolate or cortical osteoid osteoma
  • For people with painful bone metastases: first-line treatment or radiotherapy failure
  • Weight \< 140kg.
  • Target tumor accessible by HIFU-MRI
  • Maximum size of the lesion - 20cm²
  • Depth of the lesion to be treated - 4mm and 10cm
  • Subject affiliated with a health insurance social protection.
  • A subject capable of understanding research objectives and risks and giving informed and signed consent
  • Subject who has been informed of the pre-medical visit results

Exclusion

  • MRI contraindication
  • Contraindication to the use of a gadolinium contrast or hypersensitivity to gadoteric acid, meglumine or any drug containing gadolinium
  • General anesthesia contraindication
  • Non-reversible hemostasis disorders
  • Previous injury on the area to be treated (radiotherapy, surgery, ...)
  • Tumors located on the spine or skull
  • Tumors located on the ribs
  • Pathological fracture
  • For Osteoid Osteoma: nidus more than 1cm deep within cortical bone
  • Pregnant woman (pregnancy test, urinary or HCG dosage, negative to inclusion) or lactating
  • existence of dermatological pathologies
  • Subject with a known latex allergy
  • Subject under safeguarding of justice, under guardianship or curatorship
  • Subject in an exclusion period by a previous or ongoing study

Key Trial Info

Start Date :

January 19 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 9 2024

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT04803773

Start Date

January 19 2021

End Date

November 9 2024

Last Update

July 23 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hôpitaux Universitaires de Strasbourg

Strasbourg, France, 67000